Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Hepatitis C in the rituximab era.

Foran JM.

Blood. 2010 Dec 9;116(24):5081-2. doi: 10.1182/blood-2010-09-307827. No abstract available.

2.

Hepatitis C virus infection and rituximab therapy after renal transplantation.

Fabrizi F, Martin P, Elli A, Montagnino G, Banfi G, Passerini P, Campise MR, Tarantino A, Ponticelli C.

Int J Artif Organs. 2007 May;30(5):445-9.

PMID:
17551909
3.

Application of rituximab to hepatitis C-positive, ABO-incompatible renal transplantation.

Tsai MK, Yang CY, Wu MS, Lee PH.

Int J Artif Organs. 2009 May;32(5):308-9.

PMID:
19569040
4.

[Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].

Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, Yokosuka O, Takagi T, Kumagai K.

Rinsho Ketsueki. 2009 Dec;50(12):1715-9. Japanese.

PMID:
20068280
5.

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.

Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY.

Ann Hematol. 2010 Mar;89(3):255-62. doi: 10.1007/s00277-009-0806-7. Epub 2009 Aug 21.

PMID:
19697028
6.

Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.

Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P.

Arthritis Rheum. 2009 Dec;60(12):3848-55. doi: 10.1002/art.25000.

7.

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK.

J Clin Oncol. 2009 Feb 1;27(4):605-11. doi: 10.1200/JCO.2008.18.0182. Epub 2008 Dec 15.

PMID:
19075267
8.

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.

Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, Mutou Y.

Am J Hematol. 2001 Dec;68(4):292-4.

PMID:
11754421
10.

Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.

Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M.

Blood. 2010 Dec 9;116(24):5119-25. doi: 10.1182/blood-2010-06-289231. Epub 2010 Sep 7.

11.

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N.

Leuk Lymphoma. 2004 Mar;45(3):627-9.

PMID:
15160930
12.

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.

Bedognetti D, Zoppoli G, Sertoli MR, Zanardi E, Blandini P, Uccellini L, Boccardo F, Andreoli GB, Ghio R, Racchi O, Ferrarini M, De Maria A.

Int J Hematol. 2010 Mar;91(2):342-4; author reply 345-6. doi: 10.1007/s12185-010-0522-z. Epub 2010 Feb 27. No abstract available.

PMID:
20191334
13.

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P.

Blood. 2008 Jun 1;111(11):5334-41. doi: 10.1182/blood-2007-11-122713. Epub 2008 Feb 21.

14.

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab.

Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M.

Intern Med. 2006;45(11):721-4. Epub 2006 Jul 3.

15.

Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution.

Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA.

Clin Transplant. 2009 Jun-Jul;23(3):431-4. doi: 10.1111/j.1399-0012.2008.00936.x. Epub 2008 Dec 10.

PMID:
19077081
16.

Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.

Miyagawa M, Minami M, Fujii K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasui K, Itoh Y, Taniwaki M, Okanoue T, Yoshikawa T.

J Med Virol. 2008 Dec;80(12):2069-78. doi: 10.1002/jmv.21311.

PMID:
19040281
17.

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.

Ann Hematol. 2004 Jan;83(1):58-60. Epub 2003 Sep 26.

PMID:
14513286
18.

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.

Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S.

Rheumatology (Oxford). 2006 Jul;45(7):842-6. Epub 2006 Jan 17.

PMID:
16418196
19.
20.

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient.

Aksoy S, Abali H, Kilickap S, Erman M, Kars A.

Clin Lab Haematol. 2006 Jun;28(3):211-4.

PMID:
16706940

Supplemental Content

Support Center